Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-myostatin”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)Looking for participantsNCT07047144
What this trial is testing

Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

Who this might be right for
Spinal Muscular AtrophySMASpinal Muscular Atrophy Type 2+3 more
Scholar Rock, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT01958970
What this trial is testing

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

Who this might be right for
End Stage Renal DiseaseKidney DiseaseProtein Energy Wasting
Pinta Biotherapeutics 51
Large-scale testing (Phase 3)Study completedNCT05156320
What this trial is testing

Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

Who this might be right for
Spinal Muscular AtrophySpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2+7 more
Scholar Rock, Inc. 188
Large-scale testing (Phase 3)Active Not RecruitingNCT05626855
What this trial is testing

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

Who this might be right for
Spinal Muscular AtrophySpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2+7 more
Scholar Rock, Inc. 238
Early research (Phase 1)Study completedNCT01524224
What this trial is testing

A Dose-Escalation Study in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 29